Drugs for dermatological disorders (A61P17)

A   Human necessities(312083)
A61P17                 Drugs for dermatological disorders(1612)

Inhibitor of hyaluronic acid decomposition including rosemary extract and retinol acetate // 2642672
FIELD: pharmacology.SUBSTANCE: hyaluronidase inhibitor includes rosemary extract and retinol acetate in the following ratio: 0.01 - 5 wt % parts of retinol acetate per 1 wt % part of rosemary extract. Means for external use on the skin to alleviate or prevent skin problems selected from the group consisting of skin aging, wrinkled skin, rough skin, dry and rough skin, acne and atopic dermatitis, including a hyaluronidase inhibitor. The cosmetic treatment method includes rosemary extract and retinol acetate application to the subject suffering from a decrease in the hyaluronic acid level, in the following proportion: 0.01-5 wt parts of retinol acetate per 1 wt % part of rosemary extract.EFFECT: agent has a synergistic activity of hyaluronidase inhibition.3 cl, 1 dwg

System delivery and regulated expression of paracrine genes for treatment of cardiovascular and other diseases // 2642605
FIELD: medicine.SUBSTANCE: group of inventions can be used to treat heart failure with congestive heart failure (CHF), diabetes or prediabetes in vivo in a patient in need thereof. To this end, a vector is administered to a subject comprising a nucleic acid encoding a paracrine polypeptide or a peptide selected from the group consisting of cardiotonic peptide, urocortin-2 (UCn-2), urocortin-1 (UCn-1), urocortin-3 (UCn-3), brain natriuretic peptide and prostacyclin synthase, wherein the said nucleic acid encoding a paracrine polypeptide or peptide is operably linked to a promoter, wherein the vector is an adeno-associated virus (AAV), and wherein the paracrine polypeptide or peptide is expressed in a cell.EFFECT: group of inventions provides treatment or improvement of CHF, diabetes or prediabetes in a patient.24 cl, 20 dwg, 3 tbl
Agent for pyoinflammatory processes in soft tissues and mucous membranes // 2641095
FIELD: pharmacology.SUBSTANCE: invention is an agent for treatment of pyoinflammatory processes in soft tissues and mucous membranes in the form of a film that contains benzalkonium chloride, metronidazole, lidocaine hydrochloride, dimethyl sulfoxide, glycerol, sodium salt of carboxymethylcellulose and 5% solution of aminocaproic acid, with components in the agent being in a specific ratio of mass fractions.EFFECT: creation of an effective agent in the form of a film possessing antimicrobial, sorption, analgesic, wound healing and haemostatic action.4 tbl
Application of fullerene c60 aqueous solution as therapeutic agent at atopic dermatitis disease // 2641091
FIELD: pharmacology.SUBSTANCE: invention is application of a therapeutic agent for parenteral administration in atopic dermatitis, which is a water-salt solution consisting of fullerene C60, pluronic F-127 and physiological saline, where the components in the agent are in a certain ratio per ml of solution.EFFECT: reduction of allergic inflammation, skin regeneration improvement.1 tbl, 5 dwg
Composition for atopic dermatitis therapy based on fulleren // 2641041
FIELD: medicine.SUBSTANCE: composition includes an aqueous solution of fullerene C60, vaseline, sucrose palmitate, as well as parabens - nipasol and nipagin in a weight ratio of 4:3.78:2.2:0.001:0.001. The final content of fullerene in the composition is 0.005 to 0.012 wt %.EFFECT: invention allows reduction of inflammatory leukocyte infiltration of the epidermis.1 cl

Bandage with prolonged detection of active substances // 2641031
FIELD: medicine.SUBSTANCE: bandages based on polysulphated oligosaccharides showing prolonged release of said active substances, and a process for their preparation are described, wherein the method comprises the step of treating with ethylene oxide. The invention relates to the use of these bandages for wound care and for the treatment and/or prevention of scar formation and skin stretch marks.EFFECT: high release of active substances.16 cl, 4 dwg, 2 ex
Systems and compositions for postprocedure skin care and methods of application thereof // 2640504
FIELD: pharmacology.SUBSTANCE: invention is a topically-applied wound healing composition consisting of the following components: aluminium sulfate tetradecahydrate present in an amount from about 40.0 wt % to about 55.0 wt % on the basis of the weight of the topically-applied wound healing composition, calcium acetate monohydrate present in an amount from about 28.0 wt % to about 39.0 wt % on the basis of the weight of the topically-applied wound healing composition, common oat grain protein present in an amount from about 0.01 wt % to about 20 wt % on the basis of the weight of the topically-applied wound healing composition, soy protein in an amount from about 0.01 wt % to about 20 wt % on the basis of the weight of the topically-applied wound healing composition, whey protein present in an amount from about 0.01 wt % to about 20 wt % on the basis of the weight of the topically-applied wound healing composition, chitosan present in an amount from about 0.25 wt % to about 50 wt % on the basis of the weight of the topically-applied wound healing composition, potassium sorbate present in an amount from about 0.25 wt % to about 10 wt % on the basis of the weight of the topically-applied wound healing composition and dextrin present in an amount from about 5 wt % to about 50 wt % on the basis of the weight of the topically-applied wound healing composition.EFFECT: effective healing of postprocedure wounds on the skin, high stability.23 cl, 4 dwg, 8 tbl, 4 ex
Composition for atopic eczema prevention or treatment containing monoacetyldiacyl glycerine compound as active ingredient // 2640503
FIELD: pharmacology.SUBSTANCE: inventions represent: a pharmaceutical composition, a composition of the functional product of therapeutic nourishment, quasimedicine composition for preventing or treating atopic eczema containing monoacetyldiacyl glycerine of formula 2 , as an active ingredient. The invention also includes a method of preventing or treating atopic eczema, comprising of administration to a non-human patient any of the compositions described above.EFFECT: monoacetyldiacyl glycerine of this invention effectively inhibit the secretion of IL-4 and IgE, without side effects, they are non-toxic and exert an express therapeutic effect.6 cl, 8 dwg, 1 tbl, 5 ex
Anhydrous powder and liquid particles // 2640184
FIELD: chemistry.SUBSTANCE: powder is provided for use in personal care compositions containing core/shell particles having an average particle size of less than 1000 mcm, each of the particles comprising: 1) a liquid core that is substantially free of water and contains a polar liquid with a surface polarity of, at least, 24% and 2) a shell containing hydrophobic particles.EFFECT: improved powder properties.12cl, 3 ex, 3 tbl, 2 dwg

In situ crosslinked polymeric compositions and methods for them // 2640084
FIELD: medicine.SUBSTANCE: invention refers to a gel matrix composition for treatment of bleeding wounds consisting of: a) 0.1-5 wt % of sodium alginate; b) 2-25 wt % of chitosan; c) water - the rest.EFFECT: rapid healing of the tissue on which the proposed composition is applied, which is also easily applied and easily removable from the application site.12 cl, 12 dwg
Dermatological reparative means and its external use for skin care, prevention and treatment of skin lesions of various etiology // 2640026
FIELD: medicine.SUBSTANCE: invention is a dermatological reparative means containing zoosterol, lightly crosslinked acrylic polymers, representing acrylic acid homopolymer esters, cross-stitched by allyl saccharose, allyl pentaerythritol or divinyl glycol, preservatives, caustic soda and distilled water, at that, components are at a specific ratio in wt %.EFFECT: increased effectiveness of action due to high adhesion to the skin surface, increased duration of agent action, shortened duration of the healing process, enhanced regeneration of the affected skin, lack of toxicity, and suppression of external allergic reactions.4 cl, 3 tbl
Composition for topical application, containing glycerin and tannin // 2640020
FIELD: pharmacology.SUBSTANCE: invention relates to a topical formulation for treatment of skin and mucosal infections comprising glycerin in an amount of 30 to 99.99% v/v and plant proanthocyanidins; to a method for maintaining of a glycerin film on a biological surface by preparing the formulation and its application to a biological surface; to a method for skin and mucosal infections treatment, comprising the step of composition application; to a method for production of the claimed composition.EFFECT: formation of a long-term high-osmotic film on damaged surfaces, thereby keeping the lesions clean from all free contaminants.11 cl, 9 dwg, 11 ex
ethod for lymphotropic therapy of donor skin wounds // 2639847
FIELD: medicine.SUBSTANCE: method includes subcutaneous injection of free autodermoplasty 32 ED lidase diluted in 2 ml of a 2% solution of lidocaine 1 hour before the operation, then after 5-10 minutes 4 ml of etamzilate are administered 1 time per day. Then, after 24 hours, the injection course is carried out at the same spot according to the scheme: 32 units of lidase diluted in 2 ml of a 2% solution of lidocaine, then after 5-10 minutes 5 ml of actovegin is injected once every two days in the amount of 4 injections.EFFECT: use of the invention allows to reduce intraoperative blood loss, contributes to the prevention of bleeding and formation of hematomas in the donor site wound area in the postoperative period, accelerates epithelization and formation of a more delicate scar.1 ex
ethod for early rehabilitation of patients after surgeries related to benign diseases of digestive system // 2639581
FIELD: medicine.SUBSTANCE: complex impact in sanatorium-resort conditions is provided: on the background of fractional diet and mineral alkalescent water intake monitoring send intestine cleaning performed, for completion of which 200 ml of a solution containing highly-pure apple pectin in mineral water is injected, in rinse-free days microclysters with Biovestin probiotic are provided and laser exposure is provided daily at 4 points in the area of postoperative joints.EFFECT: method allows to shorten the period of medical and social rehabilitation.2 ex
Bifunctional peptide // 2639573
FIELD: biotechnology.SUBSTANCE: invention relates to the field of biotechnology, specifically to the bifunctional peptide capable of activating collagen synthesis and inhibiting matrix metalloproteinase production, and can be used in medicine and cosmetology. Bifunctional peptide has a sequence of three peptide regions a, b, and c. The first region A is hexapeptide, repeated at least three times, capable of communicating with an elastin-binding receptor protein to stimulate collagen synthesis. The second region B is tetrapeptide capable acting as a competitive inhibitor of urokinase protease and cleaving by the said protease. The third region C is tripeptide that occupies at least one active site of matrix metalloproteinases to permit inhibition of these proteinases.EFFECT: invention allows to effectively stimulate collagen synthesis and inhibit the production of matrix metalloproteinases for treatment of chronic cicatricial diseases, sores, or ulcers for skin tissue recovery or regeneration and for skin anti-aging.18 cl, 7 ex, 8 dwg
eans for intravital skin whitening near blue eyes // 2639485
FIELD: cosmetology.SUBSTANCE: means is presented that is characterized by including sodium hydrogen carbonate at a temperature of 45°C, hydrogen peroxide, lidocaine hydrochloride and water for injection, the components in the means are in a certain proportion in wt %. Local hyperthermic alkaline steaming, discoloration and loss of skin sensitivity with a warm bruise bleach solution and local anaesthetic easily penetrating the skin, in conditions that exclude skin piercing with an injection needle, additional blood vessel damage, interstitial bleeding, haemorrhage, hematoma formation, bruising, inflammation, abscess and sepsis.EFFECT: non-invasive discolouration and anaesthesia of facial skin with bruises and blue eyes.1 cl
ethod for whitening of bruise under eye // 2639283
FIELD: medicine.SUBSTANCE: during whitening, all liquid preparations are used at a temperature of 42°C. The skin in the area of bruise is previously wiped carefully with a damp cloth, intended for removing makeup, then rinsed with water, dried by a dry disposable kerchief, a cotton-gauze tampon is imposed on the entire bruise surface, the tampon is saturated with sodium bicarbonate solution, covered entirely by waterproof sheeting, a flexible heating pad with water is applied at a temperature of 42°C and used to densely press to the entire tampon area to the face surface for 3-10 min. Then the heating pad, tampon and sheeting are removed, and a water soluble colourless tampon, soaked with a solution of a bruise bleach is immediately imposed to their place, the entire tampon is covered by a waterproof colourless transparent band, and a transparent and colourless balaclava is put on the head and used to densely press them to the selected surface. Time is marked and the dynamics of skin colour in the area of the bruise is continuously observed through the balaclava. The effect is stopped, the balaclava and the band are removed when the skin is completely discoloured, or 10 minutes after the tampon is applied. After this, the face skin is rinsed with water, and if the colour is preserved, the method is repeated after 24 hours.EFFECT: method provides non-invasive skin discoloration in the area of the bruise under the eye through steaming and subsequent transcutaneous infiltration with a bruise bleach solution under conditions excluding injections and skin punctures with an injection needle, haemorrhage, bleeding, bruising, inflammation, abscess and sepsis.1 cl
ethod for local treatment of trophic ulcers of venous etiology // 2639123
FIELD: medicine.SUBSTANCE: method includes administration of platelet-enriched auto plasm and regional administration of lymphostimulating drugs at optimal doses with an effective course of treatment, with the autoplasm being administered sub bulcerously.EFFECT: application of the invention allows to achieve the restoration of microcirculation in the lower limbs area, more rapid disappearance of perifocal swelling, faster onset of necrolysis, emergence of granulation tissue in ulcers, accelerated reparation and epithelialization of a trophic ulcer.6 cl, 1 dwg
ethod for production of composition for skin regeneration // 2639094
FIELD: pharmacology.SUBSTANCE: method for production of a composition for skin regeneration, comprising juniper fruit, stems and needles placing in an extraction unit, the unit is sealed, keeping the boiling point of water inside the extractor for 12-15 hours, after which the aqueous extract solution is extracted from the unit, filtered and left in a sealed transparent container in a room without access to light until, the liquid in the vessel becomes red as a result of the fermentation process, and mould forms on its surface, which is separated from the liquid and recovered, a mixture is prepared from the resulting aqueous solution of the extract and mould formed on its surface with mould concentration of 0.5 wt % to 1 wt % in the aqueous extract solution, which is placed in a closed vessel and boiled taking periodical samples to check the amount of spores and vegetative forms of microorganisms therein, and boiling is stopped after complete disappearance of vegetative forms with the spores safety.EFFECT: skin regeneration composition obtained by the above-described method has pronounced regenerating properties.2 cl, 1 tbl, 4 ex
eans for skin infections treatment // 2639085
FIELD: medicine.SUBSTANCE: composition for skin infections treatment includes equal proportion of rifampicin and doxycycline hyclate antibiotics, 0.7-1.0% each, a solution of dimethylsulfoxide - 20-40% of the total volume, distilled water - the rest.EFFECT: increased effectiveness of antimicrobial agent's action on the infectious focus on the skin surface and in the skin layer depth.5 ex
Topical application compositions containing dapson and dapsone/adapalen, and methods for their application // 2638815
FIELD: pharmacology.SUBSTANCE: invention is a dermatological composition containing dapsone, the first solubilising agent, which is monoethyl ether diethylene glycol, polymer thickener and water, where dapsone is present in the composition at a concentration of 3 wt % to 10 wt % and the polymer thickener consists of a acrylamide/sodium acryloyldimethyltaurate copolymer.EFFECT: reduced particle size of dapsone, which leads to minimized feeling of the presence of sand when applied, and decreased dapsone dissolution in the monoethyl ether of diethylene glycol that leads to a more aesthetic appearance of the composition.19 cl, 3 dwg, 8 tbl, 6 ex

ethod for treatment of burns and scars with application of tocotrienol compositions // 2638793
FIELD: pharmacology.SUBSTANCE: composition having a 30% concentration of a tocotrienol composition containing at least 50% of vitamin E present as 10% alpha-tocopherol, 12% alpha-tocotrienol, 20.6% gamma-trienol, 1.5% beta-tocotrienol, and 5% delta-tocotrienol, is used topically or in combination with oral administration.EFFECT: effective treatment of scars and burns by increasing the level of tocotrienols in the affected tissues.42 cl, 9 dwg, 2 ex
Compounds of thienopyrimidine // 2637925
FIELD: pharmacology.SUBSTANCE: invention relates to a compound of formula I: , where group A is independently monocyclic or bicyclic aryl or heteroaryl optionally substituted by one or more A'; each group A' is independently C1-6 alkyl, halogen, cyano or heteroaryl; group R1 is tetrahydropyranyl substituted with an amino group; or pharmaceutically acceptable salts thereof, which are SYK inhibitors and are useful for treatment of autoimmune and inflammatory diseases.EFFECT: increased efficiency of treatment.10 cl, 2 tbl, 25 ex
Antibacterial protein sponge for chemotherapy of infected wounds and method of its production // 2637634
FIELD: medicine.SUBSTANCE: antibacterial protein sponge for chemotherapy of infected wounds contains protein basis, including serum albumin or serum total protein or plasma total protein and medicinal agent or agents possessing antibiotic activity against pathogens causing purulent inflammations. It also provides a method of obtaining antibacterial protein sponge, including freezing solution containing serum albumin or serum total protein or plasma total protein, keeping in frozen state, defrosting, washing resulting protein sponge from not included in its composition components, mechanical spin of free liquid from washed protein sponge swelling of squeezed protein sponge in the solution of one or more agents with antibiotic activity, freezing swelled protein sponge and its drying by lyophilization.EFFECT: new effective medical material - antibacterial protein sponge, designed for chemotherapy of infected wounds.3 cl, 5 dwg, 1 tbl, 3 ex
Skin-penetrating glycosaminoglycan compositions for topical application in cosmetics and pharmacy // 2637443
FIELD: pharmacology.SUBSTANCE: glycosaminoglycan is hyaluronan or a derivative thereof and has a molecular weight of 50-2500 kDa, is treated with an activating agent that is a reaction-limiting reagent. Next, a lipid moiety containing an amino group is introduced into the reaction, lasting from 30 minutes to 3 hours, with the activated glycosaminoglycan for the their covalent binding. The molar amount of the lipid moiety in the reaction is greater than the amount of activator used, which in turn is added in an amount to promote covalent binding of the lipid fragment with 1-7.5% of disaccharide monomer units of the glycosaminoglycan; as well as to the modified glycosaminoglycan obtained by this method, to the drug on its basis and to its application.EFFECT: improved local delivery of modified hyaluronan through the skin barrier.27 cl, 20 ex, 17 dwg
Agent for burn and wound healing // 2637440
FIELD: pharmacology.SUBSTANCE: agent having antioxidant, anti-inflammatory, antimicrobial and wound-healing activities is provided in a mild dosage form for external topical application in the form of hydrophobic ointments containing dihydroquercetin or a metal complex of dihydroquercetin with zinc of the general formula ML2(H2O)2 as a pharmacologically active substance, wherein M is a zinc ion and L is a deprotonated dihydroquercetin ligand in which the zinc ion content is 8.8-9.2%, and further comprising a hydrophobic basis with larch wax, the components in the agent being in a certain ratio, wt %.EFFECT: effective treatment of various types of wounds and burns, a wide range of therapeutic effects.2 cl, 6 ex, 9 dwg
ethod for treatment of oral mucosa chronic inflammation with hyperkeratosis elements in young persons // 2637413
FIELD: medicine.SUBSTANCE: invention is intended for treatment of oral mucosa chronic inflammation with hyperkeratosis elements (lichen acuminatus of erosive-ulcerous form, flat form of leukokeratosis). Injection of platelet-enriched plasma 0.1-0.5 ml per mm2 is performed once a week, as a course of 3 procedures, and of placental drug "Laennek" 0.1-0.2 ml per mm2, 1 injection with an interval of 2 days, as a course of 5-10 injections, the injections are carried out under the morphological elements located on the oral mucosa and "Laennec" is additionally injected intravenously, dropwise, in a dose of 4 ml dissolved in 250-500 ml of physiological solution, for the course of 10 procedures with an interval of 2 days.EFFECT: application of the method provides long-term remission due to a complex effect on the main links of the disease pathogenesis, which is manifested in the reduction of inflammatory response, normalization of local immunity, microbial contamination of the oral fluid and stabilization of free-radical oxidation of the oral fluid.2 ex

Retinoid-containing compounds for local application of "oil in water" emulsion type // 2637408
FIELD: medicine.SUBSTANCE: invention relates to a composition in the form of an oil-in-water emulsion, preferably not containing an emulsifier and containing at least one particular retinoid in a physiologically acceptable medium. A method for preparation of such composition and its application in cosmetics and dermatology is described.EFFECT: compositions are stable and well tolerated by patients.17 cl, 3 dwg, 1 tbl, 4 ex
Ointment for skin infections treatment // 2637092
FIELD: medicine.SUBSTANCE: invention can be used to treat a wide range of skin lesions infected: ulcers, eczema, wound infections, bitten wounds, pressure sores, psoriasis, herpes, leprosy. The following active ingredients per 100 g of the base are included in the composition of the ointment for skin infections treatment: rifampicin and doxycycline hyclate antibiotics in equal proportions 1-3 g each, human recombinant interferon alpha-2b 250000 - 500000 ME, the vaseline base is the rest.EFFECT: effectively overcomes the factors of pathogenic microbes resistance and expands the spectrum of action on all types of skin infectious lesions.2 ex

Pharmaceutical compositions based on shk and methods for their production and use // 2637085
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition contains a pharmaceutically acceptable salt of ShK polypeptide, consisting of a sequence of SEQ ID No. 1 attached to chemical particle through aminoethyloxiethyloxiacetyl (AEEAc) linker. The said chemical particle is selected from the group consisting of AEEAc-L-Pmp(OH2); AEAAS-D-Pmp(OH2); AEAAC-D-Pmp (OH, Et); AEAs-L-Pmp(Et2); AEAAC-D-Pmp(Et2); AEAAS-L-Tyr; AEAAS-L-Tyr(PO3H2); AEAAC-L-Phe(p-NH2); AEAAS-L-Phe(p-CO2H); AEAAS-L-aspartate; AEEAc-D-aspartate; AEESA-L-glutamate; and AEEAc-D-glutamate, and the C-terminus of the polypeptide is an acid or an amide. Also, the composition comprises a surfactant in an amount effective to dissolve the said ShK polypeptide in an aqueous carrier. The pH of the said pharmaceutical composition is 5-7.EFFECT: articles for treatment of autoimmune diseases comprising the said composition and a method for manufacture of the said pharmaceutical composition are provided.11 cl, 3 dwg, 6 tbl, 7 ex
ethod for post-operative period management for patients with open injuries of nose skeleton // 2636854
FIELD: medicine.SUBSTANCE: primary surgical treatment of wounds of the external nose and elimination of post-traumatic deformations of the osseous cartilaginous skeleton of the external nose and its cavity are performed. From the second day of the postoperative period, the wound area of the external nose is treated daily with Bepanten® plus cream, which is applied twice a day for 6-10 days before the onset of the stage of scar formation and reorganization. With the onset of this phase, laser cutting with Kontraktubeks gel is carried out for 7 days using a continuous technique in a continuous mode with a power of 10-15 mW in the area of cutaneous wounds. Exposure time is 1.5 min per point. Total exposure time is 4.5-6 min. From the fourth day of the postoperative period within 5 days, endonasal laser therapy is performed in the red range, in a pulse mode with a power of 5 W for 1.5 minutes in each half of the nasal cavity.EFFECT: method reduces the frequency of scar deformations in the external nose due to prevention of excessive scarring, elimination of inflammation and stimulation of regeneration.2 ex
Pharmaceutical compositions for treatment of wounds and burns // 2636530
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for the treatment of burns and wounds includes the following components, wt %: colloidal silver - 0.0001-0.1, colloidal zinc oxide - 5-15, glycerol - 5-15, methylcellulose - 0.05-5, distilled water is the rest. The invention provides an acceleration of tissue regeneration processes in burn wounds. The invention can be used in therapy and surgery for wound healing as a reparative, antiinflammatory and microcirculation-improving agent for the treatment of thermal, solar and chemical burns.EFFECT: composition has no local irritation or allergic effect, it can be easily removed from the skin surface and is easy to use.4 dwg, 3 ex
Drug for wound healing acceleration containing rubidium chloride in powder form // 2636523
FIELD: pharmacology.SUBSTANCE: drug for wound healing is described. The drug contains rubidium chloride in the powder form.EFFECT: invention has a highly effective action, provides expressed healing action, quickly eliminates inflammatory processes, reduces swelling on 2-3 day, significantly improves the condition of the injured tissue, accelerates reparative-degenerative processes and terms of epithelization, shows pronounced therapeutic effects in treatment of various skin lesions and mucous membrane-wounds, fractures, decubituses, trophic ulcers of various genesis, superficial burns of 1-3 degree, has no contraindications, does not cause allergic reactions.3 ex
Pharmaceutical composition for thermal injuries and wounds treatment in combination with bone damage // 2636227
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for treatment of wounds complicated by bone damage, which consists of 4 wt % to 12 wt % of beeswax and 88 wt % to 96 wt % of an extract obtained with sesame oil from initial ingredients including Radix Scutellariae, Coptis Chinensis, Cortex Phellodendri, Pericarpium Papaveris and Lumbricus, based on the total weight of the composition. Individual content of each of Radix Scutellariae, Coptis Chinensis, Cortex Phellodendri, Pericarpium Papaveris and Lumbricus, based on their dry weight, ranges from 1% to 6% of the total weight of sesame oil, respectively. Application of the pharmaceutical composition for manufacture of a drug for treatment of a thermal injury complicated by bone damage. A pharmaceutical composition for treatment of a thermal injury complicated by bone damage. A method for treatment of open injuries complicated by a fracture, a deep thermal injury with bone damage or bone necrosis.EFFECT: composition has increased effectiveness for treatment of wounds and thermal injuries complicated by bone damage.9 cl, 31 dwg, 8 ex
Drug based on 5-amino-2,3-dihydrophthalazine-1,4-dione as quick-soluble film for transbuccal introduction // 2635769
FIELD: pharmacology.SUBSTANCE: drug in the form of easily soluble biocompatible film for transbuccal application includes a therapeutically effective amount of pharmacologically active agent, such as a salt of alkaline or alkaline-earth metal 5-amino-2.3-dihydrophthalazine-1.4-dione as a waterless salt or its monohydrate or dihydrate, or their mixtures, mucoadhesive film forming polymer plasticiser and taste flavour, represented by a mixture of β-cyclodextrin or modified β-cyclodextrin with sorbitol when their mass ratio of 4:1-1:2, the content of the specified mixture in the film is 15-40 wt % of the weight of the entire film.EFFECT: increased release speed of the pharmacologically active agent when applying the film, increased transparency, uniformity and stability in storage while retaining elasticity and strength.16 cl, 5 tbl
Wound closure and healing dressing // 2635533
FIELD: medicine.SUBSTANCE: dressing on a net material with beeswax is described, into which petrolatum and/or petroleum jelly is added in an amount of 5÷95 wt.%. Plastification of beeswax with a vaseline composition and use of a net material in the dressing structure to apply a plasticized wax composition, introduction of medicinal products, including hydrophilic, and surface active substances into the dressing.EFFECT: dressing resistance to oxidation, to radiation sterilization, stability of the dressing properties for prolonged storage over a wide range of temperatures, controlled wound modeling, as well as therapeutic effect, steam and gas permeability.8 cl, 1 tbl, 20 ex

Cosmetic cream // 2635524
FIELD: cosmetology.SUBSTANCE: invention is a cosmetic cream with an anti-inflammatory and anti-acne action comprising a mixture of ceteareth-6 and stearyl alcohol, stearic acid, triethanolamine, caprylic/caproic triglyceride, glycerol, perfume and water, further comprising an aqueous dioscore extract, a combination of plant oils, namely grape seed oil and coconut oil, and as a perfume - a composition of essential oils, and the components in the cream are in a certain ratio, in wt %.EFFECT: invention provides antimicrobial activity and a decrease in the appearance of acne, an expansion of the arsenal of agents with an anti-inflammatory and regenerative effect.1 dwg, 3 tbl, 1 ex
New photographic system // 2635512
FIELD: pharmacology.SUBSTANCE: invention is a photoprotective composition consisting of only 3 or 4 solar filters comprising: one or two UV-A filters to achieve a critical wavelength of >370 nm selected from the following: 5,6,5',6'-tetraphenyl-3,3'-(1,4-phenylene)-bis[1,2,4]triazine, 1,1'-(1,4-piperazinediyl)bis[1-[2-[4-(diethylamino)-2-hydroxybenzoyl]-phenyl]-methanone, butyl methoxydibenzoylmethane (BMDBM) in an amount of less than 2 wt %, based on the total weight of mentioned composition, hexyl-2-[4-(diethylamino)-2-hydroxybenzoyl] benzoate; Subject to the mandatory presence of 5,6,5',6'-tetraphenyl-3,3'-(1,4-phenylene)-bis[1,2,4]triazine. Also included in the composition are 2,4-bis[4-(2-ethylhexyloxy)-2-hydroxyphenyl]-6-(4-methoxyphenyl)-1,3,5-triazine (BEMT), one or two filters selected among UV-B filters, provided that the solar filters do not include octocrylene, para-aminobenzoic acid (PABA) and ethylhexyl methoxy cinnamate.EFFECT: invention can significantly increase the sunscreen factor SPF, photostability, stability in relation to light, air, moisture and temperature of the composition.22 cl, 7 tbl, 4 ex
Preservative-free topical composition, including hyaluronic acid // 2635473
FIELD: pharmacology.SUBSTANCE: invention is a topical composition for stimulation of skin or mucous membranes scarring, containing less than 1 CFU/ml of aerobic flora and free of preservatives, which contains, based on the total weight of the composition: at least 0.1 wt % of hyaluronic acid, a mixture of low molecular weight hyaluronic acid having a molecular weight of 600 to 1,000 kDa, and a high molecular weight hyaluronic acid having a molecular weight of 800 to 1,200 kDa, the said high molecular weight hyaluronic acid has a higher molecular weight than the said low molecular weight hyaluronic acid; at least one agent for skin scarring and water. The invention provides a composition where the high molecular weight hyaluronic acid enhances scarring by its film-forming effect, while the low molecular weight hyaluronic acid, due to its penetrability, enhances composition components penetration into tissues.EFFECT: improved healing properties, improves the epidermis structure and accelerates the differentiation of the granulation tissue.7 cl, 2 ex, 2 tbl

Hemostatic material, hemostatic means and material based thereon // 2635465
FIELD: medicine.SUBSTANCE: material comprising a hemostatic agent O,O'-dipalmitoyl chitosan or a salt thereof and one or more bioadhesive neutral substances are described.EFFECT: increased hemostatic activity of modified chitosan, hydrophobically modified chitosan, high water solubility, increased hemostatic properties of the hemostatic material based on modified chitosan, expansion of the hemostatic arsenal.28 cl, 7 tbl, 1 dwg, 11 ex
eans for body washing based on sodium hypochlorite // 2635195
FIELD: cosmetology.SUBSTANCE: invention is a body wash composition containing sodium hypochlorite, an anionic surfactant comprising alkyl sulfate and acting as a blowing agent, a nonionic surfactant comprising an alkanol-amide and acting as a viscosity enhancing agent, an amphoteric surfactant, acting as a foaming agent and a chelating agent. The content of sodium hypochlorite is in the range from 0.1 wt % to 2 wt % of the body wash composition, the content of the anionic surfactant is in the range of from 6 wt % to 15 wt % of the body wash composition, the content of the non-ionic surfactant is in the range of 1 wt % to 7 wt % of the body wash composition, the content of the amphoteric surfactant is in the range of from 0.5 wt % to 7 wt % of the body wash composition and the content of the chelating agent is in the range of from 0.1 wt % to 0.2 wt % of the body wash composition, and the composition exhibits a pH in the range of 3.5 to 9.8.EFFECT: invention provides a stable and skin-friendly body wash composition with the desired moisturizing properties and antimicrobial properties, preserves the desired oxidative qualities of sodium hypochlorite.11 cl, 8 ex, 8 dwg
ethod for tissue regeneration stimulation // 2634576
FIELD: medicine.SUBSTANCE: tissue regeneration is stimulated by modeling a cutaneous wound in a mouse with external application of SDF-1 from the 1st to the 7th day of the wound process once a day at a dose of 5 ng and subcutaneous administration of G-CSF for 3 days 1 time per day in a dose of 125 mcg/kg (microgram/kilogram) starting from the 5th day after wound modeling.EFFECT: stimulation of skin tissues regeneration.2 tbl, 1 ex
ethod for dog demodecosis treatment // 2634265
FIELD: veterinary medicine.SUBSTANCE: as an insecticacicidal agent, the composition is used with the following proportions of components, wt %: abamectin - 0.1; fipronil - 0.5; dimethylsulfoxide - 10; ethylcellosolve 30-40; polyethylene glycol-1500 - 16; isopropyl alcohol - the rest is up to 100. The composition is locally applied to the affected parts of the animal's body at a dose of 0.03 ml/kg per animal.EFFECT: increased therapeutic effectiveness of dog demodecosis treatment.1 tbl, 3 ex
Agent for dugs treatment // 2633782
FIELD: veterinary medicine.SUBSTANCE: product contains PVA18/11 polyvinyl alcohol, a coniferous-glycerin biologically active additive, chlorhexidine 0.05% and distilled water, with components taken in a certain ratio.EFFECT: dug skin softening and wounds healing.1 cl
Paralytic shellfish poison // 2633637
FIELD: pharmacology.SUBSTANCE: use of paralytic shellfish poison (PSP) for topical treatment of pruritus in a human or other mammal, wherein PSP is a saxitoxin or tricyclic 3,4-propinhydropurine represented by the following formula (I),where R1 and R5 are independently selected from the group consisting of -H and -OH; R2 and R3 are independently selected from the group consisting of -H, -OSO3- and -SO3; and R4 is selected from the group consisting of -H, -OH, -OC(=O)NH2, -OC(=O)NHSO3- and -OC(=O)CH3, or where PSP is the salt of a saxitoxin or tricyclic 3,4-propinhydropurine. Pharmaceutical composition for topical treatment of pruritus in a human or other mammal. A method for topical treatment of pruritus in a human or other mammal.EFFECT: group can effectively treat pruritus in a human or other mammals.22 cl, 1 dwg, 2 tbl

Treatment of inflammatory damages in case of rosazea using ivermectin // 2633481
FIELD: pharmacology.SUBSTANCE: invention is a method for inflammatory damages treatment in case of rosacea in a subject in need thereof, comprising topical administration of a pharmaceutical composition containing 0.5% to 1.5% by weight of ivermectin and a pharmaceutically acceptable carrier once a day to the skin area affected by inflammatory damages at rosacea, where, 2 weeks after the initial administration of the pharmaceutical composition, a significant reduction in the amount of inflammatory damages is observed.EFFECT: significant reduction in the number of inflammatory damages at rosacea two weeks after the initial application, more effective treatment, statistically significant remission and reduced adverse skin reactions.15 cl, 5 ex, 8 tbl, 13 dwg

Papulopustular rosacea treatment by ivermectin // 2633076
FIELD: pharmacology.SUBSTANCE: invention is a method for treatment of papulopustular rosacea in a subject in need thereof, comprising topical application of a therapeutically effective amount of a pharmaceutical composition comprising ivermectin and a pharmaceutically acceptable carrier, once a day, to a region of skin afflicted with papulopustular rosacea, wherein the treatment results in a significant reduction in the number of inflammatory foci within 2 weeks after the initial application of the pharmaceutical composition.EFFECT: significant reduction in the number of inflammatory foci two weeks after the initial application without joint application of another active agent, more effective treatment, and a longer remission, a reduction in adverse skin reactions.16 cl, 12 dwg, 7 tbl, 4 ex
Heterocyclic amines and their application // 2632900
FIELD: pharmacology.SUBSTANCE: invention relates to a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein W is S; Y is N; X is N; R1 is selected from (a) C1-C6 alkyl optionally substituted with amino, methylamino, dimethylamino, C1-C6 alkoxy or isoindolyl; (B) -NR8R7, -CH2NR7R8, where R7 and R8 are joined to form optionally substituted C3-C7 non-aromatic ring which is pyrrolidine, morpholine, piperazine, piperidine, 1,4-diazepane, azepane, azetidine, 2-azabicyclo[2.2.1]heptane or 2,5-diazabicyclo[2.2.1]heptane and optionally substituted by one or more C1-C6alkyl, C1-C6alkoxy, methoxyethyl, 1-methoxypropane, isopropyloxymethyl, isopropyloxyethyl, -C(O(CH2)-methyl, -C(O)(CH2)-O-isopropyl, C1-C6haloalkyl, -S(O)2-methyl, -S(O)2-isopropyl, oxo, -C(O)(C1-C2)alkyl-N(methyl)2, -C(O)(C2)alkyl-(pyrrolidine), t-butyl-C(O)- or phenyl; or (c) -O-(tetrahydro-2H-pyran); each of R2, R3 and R5 are hydrogen; R4 is selected from C3-C6cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl and optionally substituted heteroaryl selected from pyridine, pyrazole, pyridazine, pyrimidine. The said heteroaryl is optionally substituted with 1 to 2 substituents selected from C1-C6 alkyl and CN. The invention also relates to specific compounds as defined in the claims. The compounds of the invention are intended for the manufacture of a pharmaceutical composition having an inhibitory activity against an interleukin 1 receptor associated kinase 1 (IRAK-1) and an interleukin 1 receptor associated kinase 4 (IRAK-4). The compounds of the invention are also useful in a method for treatment of a disorder sensitive to inhibition of IRAK-1-mediated signalling.EFFECT: heterocyclic amines having inhibitory activity against an interleukin 1 receptor associated kinase 1 and interleukin 1 receptor associated kinase 4.24 cl, 4 tbl, 431 ex
ethod for preventing reinfection of injured skin surface in patients when carrying out cosmetic peeling procedure // 2632707
FIELD: medicine.SUBSTANCE: during the first week before the peeling procedure, Enterosan is administered by 1 capsule 3 times a day. Then Enterosan is prescribed is a dose of 1 capsule twice a day for 20 days.EFFECT: provides prevention and relief of early complications of injured skin and acceleration of its recovery processes.5 dwg, 1 tbl, 3 ex

Treatment of malignant and non-malignant diseases with ras antagonists // 2632097
FIELD: pharmacology.SUBSTANCE: group of inventions is a Ras antagonist represented by the formula R1-R2-R3-R4, where: R3 is S; R4 is farnesyl or geranyl-geranyl, wherein geranyl-geranyl has the structure :R2 is a 5-membered heterocyclic ring containing one S heteroatom; R1 is C(=O)R5, CO2M; R5 is hydroxyl; M is a salt forming an organic or inorganic counterion; and R8is hydrogen or C1-C4 alkyl; and pharmaceutically acceptable salts thereof; or R1 is a 5-membered heterocyclic ring containing 2-4 N heteroatoms and R2 is a phenyl ring; or R2 is a 5-membered heterocyclic ring containing three heteroatoms selected from N and S, and R1 is C(=O)R10, and R10 is hydrogen, hydroxyl or C1-C4 alkyloxy. The invention also relates to a method for inhibition of Ras-induced cell proliferation associated with a malignant or non-malignant disease, comprising Ras antagonist administration to a patient.EFFECT: increased efficiency of treatment.20 cl, 9 ex, 7 dwg